RxDoctor Payments Data

Jason Go, MD

Cardiovascular Disease · Fargo, NDNPI 1447475637

Payments from drug & device makers

What this record shows

8 manufacturers reported payments, led by Medtronic at 38.0% of the total. Reporting peaked in 2023 at $5,658 and has fallen 76.1% since, to $1,350 in 2024.

$14,600in general payments, 2019–2025

Across 285 payments — averaging $51.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$6K
  • Edwards Lifesciences$5K
  • Boston Scientific$2K
  • Shockwave Medical, Inc$1K
  • Abbott$187
  • Heartflow, Inc.$144
  • plus $111 from 2 others
$573,229in research payments, 2019–2025

Across 44 payments — averaging $13,028 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novartis$457K
  • AstraZeneca$94K
  • Biotronik Inc.$16K
  • Astrazeneca UK Limited$5K
  • Medtronic$2K

What the payments were for

  • Travel & lodging$7,99055%
  • Food & beverage$6,61045%

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,600 in reported general payments places this provider in the 75th percentile of 35 cardiovascular disease providers in North Dakota.

See all cardiovascular disease providers in North Dakota

Medicare billing

Part B allowed, 2024
$236,367
Medicare patients
1,657
Services billed
3,865

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Repatha SureclickEvolocumab50$57,969
EliquisApixaban57$44,714
Praluent PenAlirocumab25$23,834
EntrestoSacubitril/Valsartan18$16,629
JardianceEmpagliflozin17$10,870
BrilintaTicagrelor14$6,462
ClopidogrelClopidogrel Bisulfate392$2,893
Ranolazine ErRanolazine33$1,861
Metoprolol Succinate97$1,469
Atorvastatin Calcium139$1,235
Rosuvastatin Calcium71$761
Isosorbide Mononitrate ErIsosorbide Mononitrate67$654
Diltiazem 24hr Er (Cd)Diltiazem Hcl42$548
Amiodarone Hcl18$374
Metoprolol Tartrate28$348

Paid to pharmacies, not to this prescriber.

Other cardiovascular disease in Fargo

See the full list for North Dakota

Where these figures come from

Is this you, or does something look wrong? →